Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa.
Africa
COVID-19
COVID-19 vaccines
SARS-CoV-2
coronavirus disease
disease control strategies
disease transmission
pandemics
public health logistics
respiratory infections
severe acute respiratory syndrome coronavirus 2
sub-Saharan Africa
vaccination coverage
vaccination programs
vaccinations
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
pubmed:
18
6
2021
medline:
24
7
2021
entrez:
17
6
2021
Statut:
ppublish
Résumé
The accelerated development of coronavirus disease (COVID-19) candidate vaccines is intended to achieve worldwide immunity. Ensuring COVID-19 vaccination is crucial to stemming the pandemic, reclaiming everyday life, and helping restore economies. However, challenges exist to deploying these vaccines, especially in resource-limited sub-Saharan Africa. In this article, we highlight lessons learned from previous efforts to scale up vaccine distribution and offer considerations for policymakers and key stakeholders to use for successful COVID-19 vaccination rollout in Africa. These considerations range from improving weak infrastructure for managing data and identifying adverse events after immunization to considering financing options for overcoming the logistical challenges of vaccination campaigns and generating demand for vaccine uptake. In addition, providing COVID-19 vaccination can be used to promote the adoption of universal healthcare, especially in sub-Saharan Africa countries.
Identifiants
pubmed: 34138694
doi: 10.3201/eid2708.203870
pmc: PMC8314831
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2009-2016Références
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Euro Surveill. 2015 Mar 26;20(12):
pubmed: 25846493
Ther Adv Drug Saf. 2019 Jul 16;10:2042098619864853
pubmed: 31360433
BMC Public Health. 2019 Jul 10;19(1):925
pubmed: 31291922
AIDS Behav. 2019 Sep;23(9):2522-2531
pubmed: 31399793
Vaccines (Basel). 2021 Feb 16;9(2):
pubmed: 33669441
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
JAMA. 2016 Mar 15;315(11):1149-58
pubmed: 26978210
Immunity. 2020 May 19;52(5):737-741
pubmed: 32433946
Drug Saf. 2020 Jun;43(6):583-593
pubmed: 32239447
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
BMJ. 2020 Dec 17;371:m4838
pubmed: 33334862
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Vaccine. 2015 May 7;33 Suppl 1:A99-108
pubmed: 25919184
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
Lancet. 2020 May 16;395(10236):1527-1529
pubmed: 32353328
Vaccine X. 2019 Jul 15;2:100034
pubmed: 31428741
BMJ. 2020 Nov 24;371:m4576
pubmed: 33234507
Clin Infect Dis. 2021 Feb 16;72(4):697-702
pubmed: 32544242
JAMA. 2020 Jun 9;323(22):2245-2246
pubmed: 32391855
Semin Immunol. 2018 Dec;40:83-94
pubmed: 30501873
Lancet. 2020 May 23;395(10237):1595-1598
pubmed: 32380041
Expert Rev Vaccines. 2019 Feb;18(2):119-131
pubmed: 30689472
PLoS Med. 2007 Mar;4(3):e73
pubmed: 17388657
N Engl J Med. 2021 May 6;384(18):1775-1777
pubmed: 33755373
Lancet. 2020 Mar 21;395(10228):935
pubmed: 32199478
Vaccine. 2010 Apr 19;28 Suppl 1:A18-25
pubmed: 20412991
Epidemiol Infect. 2009 Jul;137(7):994-1002
pubmed: 18925986
MDM Policy Pract. 2019 Dec 19;4(2):2381468319894546
pubmed: 31903423
F1000Res. 2016 Jun 23;5:1477
pubmed: 28357037
BMC Public Health. 2014 Oct 03;14:1032
pubmed: 25281354
Lancet Infect Dis. 2017 Aug;17(8):867-872
pubmed: 28545721